Mithra Obtains a Capital Commitment Agreement of EUR 50 Million from Partner LDA Capital

/in , /by

Liege, Belgium, 24 April 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into a capital commitment agreement with LDA Capital Limited, a Los Angeles based global investment group with expertise in cross border transactions in life science sector.

Read more

Mithra Releases 2019 Annual Report and Invitation to its Securities holders’ Meeting

/in , /by

Liege, Belgium, 22 April 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces the publication of its 2019 Annual Report and the invitation to its Ordinary and Extraordinary General Securities holders. 2019 Annual Report The Annual Report which outlines Mithra’s achievements in 2019 includes the following information: […]

Read more

Mayne Pharma Submits New Drug Application For E4/DRSP to the FDA

/in , /by

16 April 2020, Adelaide Australia and Liege, Belgium – Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) today announced that Mayne Pharma has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA), seeking marketing authorisation for E4/DRSP, a combined oral contraceptive indicated for the prevention […]

Read more

Mithra Announces Commercial Launch of Myring™ in Germany, the biggest market in Europe

/in , /by

Successful launch of Mithra’s hormonal contraceptive ring in Germany under the trademark MYCIRQ® Germany is the largest European market and the second worldwide, with 3 million vaginal rings sold per year Mithra CDMO pursues the manufacturing of its Myring™ orders in compliance with all the measures required by the Belgian authorities Liege, Belgium, 2 April […]

Read more

Mithra Announces Donesta® Phase III Clinical Program Update

/in , /by

Liege, Belgium, 01 April 2020 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces an update on the Donesta® Phase III Clinical Program called “E4 Comfort”, which aims at enrolling approximately 2200 menopausal women (40-65 years) and includes two pivotal studies: in North America (United States/Canada) launched in […]

Read more

Mithra Reports Full Year 2019 Financial Results

/in , /by

Record revenue (EUR 96.5 million) and EBITDA (EUR 40.7 million) increased respectively by 47% and 6%, mainly driven by U.S. deal for Estelle® Anticipated future licensing milestones for Estelle® of EUR 322 million (out of a total of EUR 486 million) Net loss significantly reduced to EUR 26.6 million (EUR 89.7 million in June 2019) thanks […]

Read more

Mithra to Host Webcast for Announcement 2019 Financial Results on 9 March 2020

/in , /by

Liege, Belgium, 05 March 2020 – 17:45  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it will host a live webcast on Monday 9 March 2020 at 15:00 CET/ 09:00 EST to announce its 2019 financial and operating results.

Read more

Mithra Receives acceptance of Marketing Authorization Application (MAA) to market Estelle® in Belgium and Luxembourg

/in , /by

Liege, Belgium, 03 March 2020 – 7:30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that the European Medicines Agency (EMA) has accepted its regulatory submission to market Estelle® in Belgium and Luxembourg.  Estelle® is Mithra’s novel combined oral contraceptive (COC) product candidate, containing 15 mg Estetrol (E4) and 3 […]

Read more

EMA Accepts Richter’s Marketing Authorization Application (MAA) for Estelle®, a Novel Combined Oral Contraceptive

/in , /by

Liege, Belgium, 27 February 2020 – 17:45  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announced that the European Medicines Agency (EMA) has accepted Gedeon Richter’s (hereinafter: “Richter”) regulatory submission for Estelle®, a combined oral contraceptive containing estetrol (E4) and drospirenone. Developed by Mithra, the product candidate is composed of […]

Read more

Mithra Announces Commercial Launch of Myring™ in Belgium

/in , /by

Mithra’s hormonal contraceptive ring is now available in pharmacies in Belgium under the trademark name Myloop® Large-scaled global commercialization of Myring™, especially in the world’s three largest markets Mithra CDMO in Belgium expected to produce nearly 2 million rings in 2020 Liege, Belgium, 12 February 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a […]

Read more